Debra Geiger, DO
Family Medicine · Richboro, PANPI 1811081722
Payments from drug & device makers
Across 169 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$381
- AstraZeneca$339
- Pfizer$304
- AbbVie$281
- Lilly USA, LLC$208
- Amgen$185
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,91699%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $381 |
| AstraZeneca | 23 | $339 |
| Pfizer | 13 | $304 |
| AbbVie(2 entities) | 20 | $281 |
| Lilly USA, LLC | 14 | $208 |
| Amgen | 11 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $152 |
| Exact Sciences | 7 | $136 |
| Biocryst US Sales Co., LLC | 1 | $127 |
| Shield Therapeutics Inc | 5 | $100 |
| GSK | 4 | $85 |
| Amarin Pharma, Inc. | 6 | $79 |
| Boehringer Ingelheim | 3 | $69 |
| Astellas Pharma US Inc | 4 | $68 |
| Sanofi Pasteur Inc. | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Johnson & Johnson | 3 | $42 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orladeyo$127
How this compares
$2,937 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 68 | $71,622 |
| OzempicSemaglutide | 39 | $39,838 |
| EliquisApixaban | 34 | $34,105 |
| JardianceEmpagliflozin | 20 | $33,915 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,149 |
| MounjaroTirzepatide | 16 | $16,580 |
| RybelsusSemaglutide | 11 | $15,473 |
| MyrbetriqMirabegron | 19 | $14,394 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,980 |
| BrilintaTicagrelor | 14 | $11,928 |
| XareltoRivaroxaban | 18 | $11,035 |
| VascepaIcosapent Ethyl | 26 | $8,925 |
| Atorvastatin Calcium | 311 | $5,199 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,769 |
| Levothyroxine Sodium | 254 | $3,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $339 | $83,55082 claims |
| Novo NordiskOzempic, Rybelsus | $381 | $55,31150 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $85 | $36,89861 claims |
| PfizerEliquis | $304 | $34,10534 claims |
| Boehringer IngelheimJardiance | $69 | $33,91520 claims |
| Lilly USA, LLCMounjaro | $208 | $16,58016 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $14,39419 claims |
| Johnson & JohnsonXarelto | $42 | $11,03518 claims |
| AbbVieSynthroid | $281 | $2,39632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Richboro
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.